Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Mar 6;25(5):3079.
doi: 10.3390/ijms25053079.

Advanced Therapy Medicinal Products as Potential Therapeutic Strategy against COVID-19 and Immune-Related Disorders

Panagiotis Mallis  1   2 , Efstathios Michalopoulos  1 , Catherine Stavropoulos-Giokas  1
Affiliations
Editorial

Advanced Therapy Medicinal Products as Potential Therapeutic Strategy against COVID-19 and Immune-Related Disorders

Panagiotis Mallis et al. Int J Mol Sci. .

Abstract

Advanced Therapy Medicinal Products (ATMPs) comprise a heterogenous class of innovative medicinal products, which further require extensive preclinical and clinical assessments before their broader use in the general population [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Gonçalves E. Advanced Therapy Medicinal Products: Value Judgement and Ethical Evaluation in Health Technology Assessment. Eur. J. Health Econ. 2020;21:311–320. doi: 10.1007/s10198-019-01147-x. - DOI - PMC - PubMed
    1. Jönsson B., Grace H., Michaels J., Towse A., Graf Von Der Schulenburg J.-M., Olivier W. Advanced Therapy Medicinal Products and Health Technology Assessment Principles and Practices for Value-Based and Sustainable Healthcare. Eur. J. Health Econ. 2019;20:427–438. doi: 10.1007/s10198-018-1007-x. - DOI - PMC - PubMed
    1. Iglesias-Lopez C., Agustí A., Obach M., Vallano A. Regulatory Framework for Advanced Therapy Medicinal Products in Europe and United States. Front. Pharmacol. 2019;10:921. doi: 10.3389/fphar.2019.00921. - DOI - PMC - PubMed
    1. FDA. CBER . Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products Draft Guidance for Industry and Food and Drug Administration Staff Contains Nonbinding Recommendations Draft-Not for Implementation. Center for Biologics Evaluation and Research; Silver Spring, MD, USA: 2014.
    1. Kirtipal N., Bharadwaj S., Kang S.G. From SARS to SARS-CoV-2, Insights on Structure, Pathogenicity and Immunity Aspects of Pandemic Human Coronaviruses. Infect. Genet. Evol. 2020;85:104502. doi: 10.1016/j.meegid.2020.104502. - DOI - PMC - PubMed

Publication types